Ip Licensing was Lexaria Bioscience’s largest product and service line in fiscal 2025, bringing in $696.00K of $705.92K (99%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Ip Licensing | $457.99K | $696.00K | |||
| Licensing Revenue | — | — | |||
| License | — | — | |||
| Product | — | — | |||
| B2B | $5.39K | $9.92K | |||
| Cargo & Freight | — | — | |||
| Other | $900 | — | |||
| Freight Revenuet | — | — | |||
| Freightrevenue | — | — | |||
| Total | $464.28K | $705.92K |
Lexaria Bioscience brought in $705.92K from its two product and service lines in fiscal 2025, the year ended August 31, 2025. Lexaria Bioscience regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $464.28K. Ip Licensing was the largest at $696.00K (98.6%), ahead of B2B at $9.92K (1.4%).
Lexaria Bioscience stopped reporting Other as a separate line after fiscal 2024, when it brought in $900.
Us was Lexaria Bioscience’s largest region in fiscal 2018, bringing in $258.29K of $433.29K (60%).
| Geography | FY 2018 |
|---|---|
| Us | $258.29K |
| Ca | $175.00K |
| Total | $433.29K |
Lexaria Bioscience brought in $433.29K from its two regions in fiscal 2018, the year ended August 31, 2018. Us was the largest at $258.29K (59.6%), ahead of Ca at $175.00K (40.4%).
Lexaria Bioscience (LEXX) reports its revenue by product and service and by geography. In fiscal 2025, Ip Licensing was its largest product and service line, bringing in $696.00K (98.6% of the total), followed by B2B at $9.92K (1.4%).
Ip Licensing was Lexaria Bioscience's largest product and service line in fiscal 2025, bringing in $696.00K, or 98.6% of the $705.92K total across its two product and service lines.
Us was Lexaria Bioscience's largest region in fiscal 2018, bringing in $258.29K, or 59.6% of the $433.29K total across its two regions.
Every figure comes from Lexaria Bioscience's annual financial filings, as reported. Each line keeps the name Lexaria Bioscience gives it, and years follow its fiscal calendar.
Lexaria Bioscience's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.